← Oncology Approval Tracker

FDA DECISION ·

Abecma

idecabtagene vicleucel · Bristol Myers Squibb / bluebird bio

FDA approvalNew therapyMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with relapsed or refractory multiple myeloma after four or more prior treatment lines that included an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 monoclonal antibody.

LAMPGEN ANALYSIS

Why it matters

The original BCMA-directed CAR T action targeted previously treated myeloma after exposure to three drug classes.

What research teams should watch

Collect prior regimens and coordinate referral, leukapheresis, manufacture, infusion and post-infusion monitoring.

PRIMARY RECORDS

Sources